Compare Manulife Financial Corporation (MFC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs TransMedics Group Inc — how do they compare? Manulife Financial Corporation trades at $43.58 (market cap $69.48B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Manulife Financial Corporation is far larger — about 25.4× TransMedics Group Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and TransMedics Group Inc for 24 Days on average.
| MFC | TMDX | |
|---|---|---|
Market Cap | $69.48B | $2.74B |
Volume | 1,347,508 | 949,331 |
Sector | Financials | Health |
52-Week High | $44.77 | $150.42 |
52-Week Low | $31.64 | $61.99 |
Typical Hold Time | 119 Days | 24 Days |
Enterprise Value | $64.75B | $3.13B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $41.67, down 2.94% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and executive appointments signal confidence in long-term strategy.
MFC presents a mixed outlook with strong profitability metrics (11.7% net margin, 13.88% ROE) and analyst consensus favoring Buy ratings (57%), but faces technical headwinds and premium valuation concerns. The stock trades above the $34.24 consensus target, suggesting limited near-term upside despite operational strength and dividend stability.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
